Overcoming Challenges in Glioblastoma Treatment: Targeting Infiltrating Cancer Cells and Harnessing the Tumor Microenvironment

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2024 Jan 8

PMID 38188666

Authors

Mario Chiariello

Giovanni Inzalaco

Virginia Barone

Lisa Gherardini

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GB) is a highly malignant primary brain tumor with limited treatment options and poor prognosis. Despite current treatment approaches, including surgical resection, radiation therapy, and chemotherapy with temozolomide (TMZ), GB remains mostly incurable due to its invasive growth pattern, limited drug penetration beyond the blood-brain barrier (BBB), and resistance to conventional therapies. One of the main challenges in GB treatment is effectively eliminating infiltrating cancer cells that remain in the brain parenchyma after primary tumor resection. We've reviewed the most recent challenges and surveyed the potential strategies aimed at enhancing local treatment outcomes.

Citing Articles

Sesquiterpene Lactones as Promising Anti-Glioblastoma Drug Candidates Exerting Complex Effects on Glioblastoma Cell Viability and Proneural-Mesenchymal Transition.

Markov A, Moralev A, Odarenko K Biomedicines. 2025; 13(1).

PMID: 39857717 PMC: 11761231. DOI: 10.3390/biomedicines13010133.

Pentraxin 3: A Main Driver of Inflammation and Immune System Dysfunction in the Tumor Microenvironment of Glioblastoma.

Scuderi S, Ardizzone A, Salako A, Panto G, Luca F, Esposito E Cancers (Basel). 2024; 16(9).

PMID: 38730589 PMC: 11083335. DOI: 10.3390/cancers16091637.

References

Moody C, Durham P, Dayton P, Brudno Y . Loading Intracranial Drug-Eluting Reservoirs Across the Blood-Brain Barrier With Focused Ultrasound. Ultrasound Med Biol. 2023; 49(7):1679-1685. PMC: 10192093. DOI: 10.1016/j.ultrasmedbio.2023.03.012. View

Mehta N, Shah H, Ben-Shalom N, DAmico R . Sonolucent cranioplasty: Is therapeutic FUS the next frontier?. J Clin Neurosci. 2023; 114:129-130. DOI: 10.1016/j.jocn.2023.06.016. View

Goel H, Kalra V, Kumar Verma S, Dubey S, Tiwary A . Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. J Control Release. 2021; 341:782-811. DOI: 10.1016/j.jconrel.2021.12.009. View

Fisher J, Adamson D . Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines. 2021; 9(3). PMC: 8004675. DOI: 10.3390/biomedicines9030324. View

Bianco J, Bastiancich C, Joudiou N, Gallez B, des Rieux A, Danhier F . Novel model of orthotopic U-87 MG glioblastoma resection in athymic nude mice. J Neurosci Methods. 2017; 284:96-102. DOI: 10.1016/j.jneumeth.2017.04.019. View

Caverzan M, Beauge L, Oliveda P, Cesca Gonzalez B, Buhler E, Ibarra L . Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies. Brain Sci. 2023; 13(4). PMC: 10136702. DOI: 10.3390/brainsci13040542. View

Sonabend A, Gould A, Amidei C, Ward R, Schmidt K, Zhang D . Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023; 24(5):509-522. PMC: 10256454. DOI: 10.1016/S1470-2045(23)00112-2. View

Zampieri L, Sboarina M, Cacace A, Grasso D, Thabault L, Hamelin L . Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells. Int J Mol Sci. 2021; 22(21). PMC: 8584761. DOI: 10.3390/ijms222111938. View

Bras J, Jesus T, Prazeres H, Lima J, Soares P, Vinagre J . TERTmonitor-qPCR Detection of Mutations in Glioma. Genes (Basel). 2023; 14(9). PMC: 10530400. DOI: 10.3390/genes14091693. View

10.

Barbieri F, Bosio A, Pattarozzi A, Tonelli M, Bajetto A, Verduci I . Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives. J Exp Clin Cancer Res. 2022; 41(1):53. PMC: 8822754. DOI: 10.1186/s13046-021-02213-0. View

11.

Sperring C, Argenziano M, Savage W, Teasley D, Upadhyayula P, Winans N . Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma. Neurooncol Adv. 2023; 5(1):vdad044. PMC: 10195574. DOI: 10.1093/noajnl/vdad044. View

12.

Triguero D, Buciak J, Yang J, Pardridge W . Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci U S A. 1989; 86(12):4761-5. PMC: 287353. DOI: 10.1073/pnas.86.12.4761. View

13.

Martinez P, Nault G, Steiner J, Wempe M, Pierce A, Brunt B . MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model. Neurooncol Adv. 2023; 5(1):vdad111. PMC: 10547466. DOI: 10.1093/noajnl/vdad111. View

14.

Wang W, He H, Zeng S, Cho H, Minea R, Swenson S . Enhanced brain entry of checkpoint-inhibitory therapeutic antibodies facilitated by intraarterial NEO100 in mouse models of brain-localized malignancies. J Neurosurg. 2023; 139(3):822-830. DOI: 10.3171/2022.12.JNS221285. View

15.

Jones D, Whitehead C, Dinevska M, Widodo S, Furst L, Morokoff A . Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells. Mol Cell Biochem. 2022; 478(6):1251-1267. PMC: 10164021. DOI: 10.1007/s11010-022-04584-0. View

16.

Moretti I, Lerario A, Sola P, Macedo-da-Silva J, Baptista M, Palmisano G . GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status. Cancers (Basel). 2023; 15(3). PMC: 9913744. DOI: 10.3390/cancers15030587. View

17.

Gu W, Fan R, Quan J, Cheng Y, Wang S, Zhang H . Intracranial In Situ Thermosensitive Hydrogel Delivery of Temozolomide Accomplished by PLGA-PEG-PLGA Triblock Copolymer Blending for GBM Treatment. Polymers (Basel). 2022; 14(16). PMC: 9413267. DOI: 10.3390/polym14163368. View

18.

Szeliga M, Rola R . Menadione Potentiates Auranofin-Induced Glioblastoma Cell Death. Int J Mol Sci. 2022; 23(24). PMC: 9778806. DOI: 10.3390/ijms232415712. View

19.

Gherardini L, Vetri Buratti V, Maturi M, Inzalaco G, Locatelli E, Sambri L . Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models. Sci Rep. 2023; 13(1):4630. PMC: 10030813. DOI: 10.1038/s41598-023-31811-5. View

20.

Schiffer D, Mellai M, Bovio E, Bisogno I, Casalone C, Annovazzi L . Glioblastoma niches: from the concept to the phenotypical reality. Neurol Sci. 2018; 39(7):1161-1168. DOI: 10.1007/s10072-018-3408-0. View